The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Exenatide (Byetta®) has been accepted for use as adjunctive therapy to basal insulin with or without metformin and/or pioglitazone in adults with type 2 diabetes who have not achieved adequate glycaemic control with these agents.
Pregabalin oral solution (Lyrica®) has been accepted for restricted use in the treatment of peripheral and central neuropathic pain in adults and as adjunctive therapy in adults with partial seizures with or without secondary generalization. The solution should be used only for patients who find it difficult to or are unable to swallow tablets. It is also recommended that treatment in these conditions is started after trials of more established agents have provided inadequate response or not been tolerated. In the case of treating partial seizures treatment should be initiated by clinicians with experience in the treatment of epilepsy. Use in the treatment of Generalised Anxiety Disorder (GAD) in adults was rejected as the manufacturer failed to make a submission for this indication.
Tobramycin inhalation powder (TOBI Podhaler®) has been accepted for as a suppressive therapy of chronic pulmonary infection due to Pseudomonas aeruginosa in adults and children aged 6 years and older with cystic fibrosis.
Triptorelin pamoate (Salvacyl®) has been rejected for reversible reduction of testosterone to castrate levels in order to decrease sexual drive in adult men with severe sexual deviations. The manufacturer failed to make a submission.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.